BidaskClub upgraded shares of MacroGenics (NASDAQ:MGNX) from a strong sell rating to a sell rating in a research note released on Friday.

A number of other equities analysts also recently weighed in on MGNX. Zacks Investment Research downgraded shares of MacroGenics from a hold rating to a sell rating in a research note on Wednesday, January 3rd. ValuEngine lowered shares of MacroGenics from a sell rating to a strong sell rating in a research report on Tuesday, November 14th. Citigroup increased their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the stock a neutral rating in a research report on Friday, November 10th. Wedbush reissued an outperform rating and issued a $44.00 price objective on shares of MacroGenics in a research report on Monday, September 11th. Finally, Raymond James Financial reissued a buy rating on shares of MacroGenics in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $30.10.

MacroGenics (NASDAQ:MGNX) traded down $0.38 during trading hours on Friday, reaching $19.55. 106,630 shares of the company’s stock were exchanged, compared to its average volume of 161,400. The stock has a market capitalization of $733.88, a P/E ratio of -4.34 and a beta of 2.73. MacroGenics has a 12 month low of $14.36 and a 12 month high of $22.31.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.97) EPS. analysts forecast that MacroGenics will post -0.7 EPS for the current year.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at approximately $700,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in MGNX. Russell Investments Group Ltd. acquired a new position in MacroGenics during the 2nd quarter worth $133,000. Schwab Charles Investment Management Inc. grew its holdings in MacroGenics by 21.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 148,792 shares of the biopharmaceutical company’s stock worth $2,606,000 after acquiring an additional 25,823 shares in the last quarter. Rhumbline Advisers grew its holdings in MacroGenics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 40,105 shares of the biopharmaceutical company’s stock worth $702,000 after acquiring an additional 3,755 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in MacroGenics during the 2nd quarter worth $438,000. Finally, SG Americas Securities LLC grew its holdings in MacroGenics by 92.2% during the 2nd quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 5,187 shares in the last quarter. 85.77% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/macrogenics-mgnx-upgraded-at-bidaskclub/1798936.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with Analyst Ratings Network's FREE daily email newsletter.